NASDAQ:WVE • SG9999014716
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for WAVE LIFE SCIENCES LTD (WVE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-05 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-02-03 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-15 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-12 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-12-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-12-09 | Clear Street | Maintains | Buy -> Buy |
| 2025-12-09 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-12-09 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-12-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-09 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-11 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-11-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-15 | Clear Street | Initiate | Buy |
| 2025-09-04 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-04 | Canaccord Genuity | Initiate | Buy |
| 2025-07-31 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-28 | Oppenheimer | Initiate | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 113.305M 3,004.25% | 108.302M -4.42% | 42.727M -60.55% | 38.567M -9.74% | 84.821M 119.93% | 184.87M 117.95% | 264.97M 43.33% | 615.91M 132.45% | 763.13M 23.90% | 1.135B 48.73% | 1.607B 41.59% | |
| EBITDA YoY % growth | -62.996M 59.66% | -106.507M -69.07% | -211.943M -98.99% | -209.531M 1.14% | -245.94M -17.38% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -67.996M 58.21% | -110.403M -62.37% | -215.383M -95.09% | -241.585M -12.17% | -219.752M 9.04% | -111.606M 49.21% | -155.716M -39.52% | 132.43M 185.05% | 201.03M 51.80% | 424.77M 111.30% | 762.21M 79.44% | |
| Operating Margin | -60.01% | -101.94% | -504.09% | -626.40% | -259.08% | -60.37% | -58.77% | 21.50% | 26.34% | 37.42% | 47.43% | |
| EPS YoY % growth | -0.55 74.18% | -0.79 -43.64% | -1.22 -54.43% | -1.36 -11.38% | -1.30 4.29% | -1.15 11.78% | -0.40 65.04% | 1.32 429.54% | 1.90 43.66% | 3.40 79.12% | 5.43 59.76% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.33 -14.19% | -0.34 -9.89% | -0.33 -1.95% | -0.31 -2.87% |
| Revenue Q2Q % growth | 10.115M 10.25% | 8.672M -0.31% | 11.57M 52.08% | 22.674M 31.49% |
| EBITDA Q2Q % growth | -65.956M -34.80% | -53.325M -4.52% | -51.35M 4.48% | N/A |
| EBIT Q2Q % growth | -63.993M -28.49% | -64.265M -21.81% | -60.896M -8.06% | -55.176M 2.29% |
All data in USD
20 analysts have analysed WVE and the average price target is 34.17 USD. This implies a price increase of 187.14% is expected in the next year compared to the current price of 11.9.
WAVE LIFE SCIENCES LTD (WVE) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of WAVE LIFE SCIENCES LTD (WVE) is -0.33 USD and the consensus revenue estimate is 10.12M USD.
The expected long term growth rate for WAVE LIFE SCIENCES LTD (WVE) is 63.77%.